Home    Contact Us    Send to Colleague    Search 

2 Mar 2011
Product in Phase IIB

Compound available for licensing and/or development partnership.  This product has been designated an orphan drug by the FDA for the treatment of Scleroderma.  Additional patent is pending for the treatment of Rheumatoid Arthritis.

Return to Press Releases

© 2019 by Commercial Healthcare Partners. Website Design & Development by Birchwood Group   Commercial Healthcare Partners    Jim Usry